Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19 - Infinity Accéder directement au contenu
Article Dans Une Revue Annals of Internal Medicine Année : 2020

Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19

Résumé

Background:A subset of patients with coronavirus dis-ease 2019 (COVID-19) will develop acute respiratory distresssyndrome and require mechanical ventilation. Studies sug-gest that many patients with COVID-19 and acute respiratorydistress syndrome experience a cytokine storm characterizedby fever; hyperferritinemia; and a massive release of inflam-matory cytokines, including interleukin-6, tumor necrosisfactor-, and monocyte chemoattractant proteins (1). Thesefindings led to the hypothesis that biological agents targetingspecific cytokine or inflammatory pathways may improve therespiratory outcomes of patients with the most severe formsof COVID-19 (2)

Dates et versions

hal-03185056 , version 1 (30-03-2021)

Identifiants

Citer

Stanislas Faguer, Arnaud del Bello, Florence Abravanel, Marie-Laure Nicolau-Travers, Nassim Kamar. Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19. Annals of Internal Medicine, 2020, 173 (6), pp.501-503. ⟨10.7326/L20-0419⟩. ⟨hal-03185056⟩
22 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More